In addition, receptor tyrosine kinase-dependent ERK1 and ERK2 activation following PI3K/AKT/mTOR inhibition have also been described in preclinical models of HER2-positive breast tumours [23,42]. The gene discussed is AKT1; the disease is breast neoplasm.